this, from a different article, to clarify:
But why had the agency already conveyed concerns about disclosure to the drug maker? This was not the first time that LIGHT study data was disclosed inappropriately, according to the FDA. Prior to the Contrave approval last fall, the agency learned that Orexigen had shared interim study results with “more individuals than FDA considered necessary to prepare a regulatory submission.” In the spirit of full disclosure, I am not an investor - short or long - in OREX.
regardless of the "eventual conclusion from the analysis of the total study data", which won't be known for a long time, I'm not sure you can argue that - having been reprimanded before about the very same type of premature release of study data - leadership did not err ("innocently" is to be debated by others with more knowledge of events than myself) in releasing for public consumption interim data from a partial study. would love to hear the argument for releasing the data...even in a patent app...when you've been "scolded" before. just not a good PR move, imo. but jmho.
you can't know, when so many are saying the results are not reliable...of course, it's your decision whether to rely on them or not; but, the FDA has made their stance pretty clear.
but, didn't the release results of the interim testing in connection with a patent app for a new CV indication? isn't that what the FDA is upset over? am I reading it right? seems some believe that management put out the info in the patent app in order to get the "interim results" into the public space, therefore letting very preliminary results be consumed by investors and others with an interest in the stock price - which, after dissemination of the info skyrocketed. seems such limited disclosure would not be the proper way to release the info, and that it may have been too soon to release it at all. I personally did not see the information before it hit the message board...so, I missed the spike.
the news this morning is not very friendly towards OREX...Forbes particularly critical.
there are others who focus only on earnings, or lack thereof, but looks like cash almost doubled and net loss decreased...both positives. agree with posters commenting re: stock price spike if/when IP settlements come.
actually, I read the officers knocked & identified themselves. not exactly a "no-knock", surprise raid...jmo.
not sure a "witness" who was a friend of the deceased in a home where a drug warrant was being served is what you need to focus on...but, up to you. also, not sure you're informed as to the visit at all.
how do shorts plan to muddy the investing waters today? TASR already moving up on fundamentals - basically, that it OWNS the smart weapon and bodycam space; the COMPETITION's own complaints tell us they are a MONSTER that is difficult to slay when they call on potential customers. What better company to invest your hard-earned dollars in? imo, a very good long-term investment based on current & future demand for its products & services. Even the COMPETITION tells you they're tough to beat...
will Taser be there? I mean, they're the leader, right?
let us know when the demonstration results in sales...
doing better today than the day I bought...that's what it's all about, right, countryboy?
then, maybe a subtitle about how management intends to insure more of it hits the bottom line...
possibly sitting alone in a parking lot, after a failed sales meeting.
maybe it was the whiny competitor...or the other whiny competitor...maybe that's all it takes to "break" a non-story.